Uploaded December 2025 | Updated November 2026, 2 days ago
Presented By: Dr. Arne Materna
Speaker Biography: He joined Bio-Me as Chief Technology Officer in 2023 and was appointed Co-CEO on July 1, 2024. In addition to his leadership role, Dr. Materna serves as a member of Bio-Me’s Board of Directors. A recognized expert in the development and commercialization of market-leading assay and BioIT technologies for microbiome and infectious disease applications, Dr. Materna brings a proven track record of impactful contributions. He has held senior management and executive roles at leading life sciences companies, including CLC bio, QIAGEN, CosmosID, and Ares Genetics.Dr. Materna earned his PhD in molecular biology from the University of Konstanz, Germany, and further specialized in microbial genomics and microbiome research as a postdoctoral fellow and leader of an experimental research laboratory at the Massachusetts Institute of Technology (MIT).
Webinar: From Dysbiosis to Detection: Exploring the Impact of Vaginal Microbiome Testing on Reproductive Success
Webinar Abstract: Infertility affects one in six couples, with fertility treatments facing daunting 2:1 odds of failure versus success. Emerging research highlights the critical role of vaginal microbiome health in reproductive outcomes. Dysbiosis and other microbiological conditions of the female genitourinary system have been strongly linked to poor fertility outcomes. However, routine infertility care is hindered by the lack of standardized diagnostic tools for microbiome characterization. Current standard of care tests are not suitable for microbiome profiling, and common approaches for microbiome analysis, such as sequencing, face significant technical limitations when applied to vaginal specimens.
This presentation reviews key studies connecting vaginal microbiome health to fertility outcomes and examines the technical barriers to vaginal microbiome analysis. It introduces PMP™, a precision microbiome profiling method utilizing highly parallelized single-plex quantitative PCR, and discusses its potential for routine use in infertility care, including applications in blended care models.
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Presented By: Dr. Arne Materna
Speaker Biography: He joined Bio-Me as Chief Technology Officer in 2023 and was appointed Co-CEO on July 1, 2024. In addition to his leadership role, Dr. Materna serves as a member of Bio-Me’s Board of Directors. A recognized expert in the development and commercialization of market-leading assay and BioIT technologies for microbiome and infectious disease applications, Dr. Materna brings a proven track record of impactful contributions. He has held senior management and executive roles at leading life sciences companies, including CLC bio, QIAGEN, CosmosID, and Ares Genetics.Dr. Materna earned his PhD in molecular biology from the University of Konstanz, Germany, and further specialized in microbial genomics and microbiome research as a postdoctoral fellow and leader of an experimental research laboratory at the Massachusetts Institute of Technology (MIT).
Webinar: From Dysbiosis to Detection: Exploring the Impact of Vaginal Microbiome Testing on Reproductive Success
Webinar Abstract: Infertility affects one in six couples, with fertility treatments facing daunting 2:1 odds of failure versus success. Emerging research highlights the critical role of vaginal microbiome health in reproductive outcomes. Dysbiosis and other microbiological conditions of the female genitourinary system have been strongly linked to poor fertility outcomes. However, routine infertility care is hindered by the lack of standardized diagnostic tools for microbiome characterization. Current standard of care tests are not suitable for microbiome profiling, and common approaches for microbiome analysis, such as sequencing, face significant technical limitations when applied to vaginal specimens.
This presentation reviews key studies connecting vaginal microbiome health to fertility outcomes and examines the technical barriers to vaginal microbiome analysis. It introduces PMP™, a precision microbiome profiling method utilizing highly parallelized single-plex quantitative PCR, and discusses its potential for routine use in infertility care, including applications in blended care models.
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc










